ArticleOrphanet journal of rare diseases2026
Mutational spectrum of EDA, EDAR, EDARADD, and WNT10A genes in the largest cohort of Russian patients with hypohidrotic ectodermal dysplasia.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundHypohidrotic ectodermal dysplasia (HED) encompasses a group of rare genetic disorders affecting two or more ectodermal derivatives (hair, teeth, nails, certain glands). The condition can be inherited in an X-linked, autosomal dominant, or autosomal recessive manner, with the majority of cases caused by mutations in the EDA, EDAR, EDARADD, and WNT10A genes. This study aimed to evaluate the distribution of pathogenic and likely pathogenic variants in 261 unrelated families affected by HED in the Russian Federation (comprising 455 patients in total) between 2007 and 2024. To achieve this objective, we employed Sanger sequencing, targeted gene panel sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), and segregation analysis to clarify the pathogenicity of variants of uncertain significance.
resultsA total of 261 unrelated probands, comprising 196 males (75.1%) and 65 females (24.9%), were included. Pathogenic or likely pathogenic variants were identified in 183 probands (70.1%). The distribution of mutated genes was as follows: EDA (n = 155, 84.7%), WNT10A (n = 16, 8.8%), and EDAR (n = 12, 6.5%). No apparent pathogenic mutations were detected in EDARADD. Additionally, we report 46 novel causative variants for HED, along with recurrent mutations in the EDA, WNT10A, and EDAR genes. We also identified that 28.8% of all causative variants in EDA are de novo.
conclusionThis is the only molecular study conducted in the Russian population affected by HED and represents the largest HED cohort published to date globally. Our findings significantly expand the mutational spectrum of HED-causing genes and will aid in choosing an initial diagnostic approach for HED patients. Further studies using whole-genome sequencing (WGS) will help to identify other contributory genes in the remaining uncharacterized Russian patients with HED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.